PharmaNutra anticipates information on the preliminary consolidated revenues of the first half of 2019
Published: 29 July 2019 10:42
The Group’s growth trend is confirmed and it announces the purchase of the building that will hold its first own production site.
PharmaNutra S.p.A. would like to announce having anticipated the preliminary consolidated revenues of the first half of 2019, not audited.
In the first six months of the current year, the PharmaNutra Group registered consolidated revenues for about 25 million Euro, up about 13.6% compared to the same period 2018. A result achieved thanks to the ongoing consolidation of activities on the Italian and foreign markets. The total, detailed results for the first half of 2019 will be circulated after the Board of Directors’ meeting called to approve the interim financial statements on 16ᵗʰ September 2019.
PharmaNutra would also like to announce that on Thursday 25ᵗʰ July it signed the notary agreement for the purchase of the area that will hold the Group’s new production and R&D site, confirming its localisation in the province of Pisa. An important step for the commercial strategies of the company, already committed to protecting the formulas and proprietary processes, which will soon lead to internal, autonomous management of the most sensitive production stages.
An aspect – that ability to invent, test and protect the proprietary formulas whose effectiveness has been proven by the extraordinary amount of research and scientific publications published over the years, besides the obvious commercial results achieved – that has always characterised the entrepreneurial action of the brothers Andrea and Roberto Lacorte.
“We have 6 specific patents related to products with an average twenty-year duration, supported by 91 clinical studies published and 27 ongoing studies”, declared the President of PharmaNutra S.p.A. Andrea Lacorte. “The investment in the new factory is an important step further strengthening company growth thanks to full control of the production of our sucrosomial solutions and the chance to reduce R&D times. We take great pride in this project and are even prouder to be able to share it with our investors”.